Ra Capital Management, L.P. Sells 25,027 Shares of Vor Biopharma (NASDAQ:VOR) Stock

Key Points

• Ra Capital Management, L.P. sold 25,027 shares of Vor Biopharma at an average price of $28.11, totaling approximately $703,508.97, which resulted in a 1.75% decrease in their direct ownership.
• The stock of Vor Biopharma has recently traded down to $26.50, after experiencing a significant drop from its 52-week high of $65.80.
• Institutional investors now own 97.29% of Vor Biopharma's stock, indicating strong institutional interest in the company.

Vor Biopharma Inc. (NASDAQ:VOR - Get Free Report) Director Ra Capital Management, L.P. sold 25,027 shares of the company's stock in a transaction on Tuesday, October 21st. The shares were sold at an average price of $28.11, for a total value of $703,508.97. Following the transaction, the director directly owned 1,401,226 shares in the company, valued at $39,388,462.86. This represents a 1.75% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Monday, October 20th, Ra Capital Management, L.P. sold 92,023 shares of Vor Biopharma stock. The shares were sold at an average price of $29.67, for a total value of $2,730,322.41.
• On Friday, October 17th, Ra Capital Management, L.P. sold 260,859 shares of Vor Biopharma stock. The shares were sold at an average price of $29.39, for a total value of $7,666,646.01.
• On Thursday, October 16th, Ra Capital Management, L.P. sold 151,803 shares of Vor Biopharma stock. The shares were sold at an average price of $29.45, for a total value of $4,470,598.35.
• On Wednesday, October 15th, Ra Capital Management, L.P. sold 51,363 shares of Vor Biopharma stock. The shares were sold at an average price of $30.55, for a total value of $1,569,139.65.

Vor Biopharma Price Performance

Shares of NASDAQ VOR traded down $1.27 during trading on Wednesday, reaching $26.50. 294,423 shares of the stock traded hands, compared to its average volume of 524,332. Vor Biopharma Inc. has a 52-week low of $2.62 and a 52-week high of $65.80. The firm has a 50-day moving average of $35.96. The stock has a market cap of $181.53 million, a PE ratio of -0.10 and a beta of 2.07.

Vor Biopharma (NASDAQ:VOR - Get Free Report) last issued its earnings results on Tuesday, August 12th. The company reported ($43.60) EPS for the quarter, missing the consensus estimate of ($11.40) by ($32.20).

Wall Street Analysts Forecast Growth

Several brokerages have commented on VOR. Baird R W upgraded Vor Biopharma from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, October 15th. Weiss Ratings restated a "sell (d-)" rating on shares of Vor Biopharma in a research note on Wednesday, October 8th. Wedbush restated an "outperform" rating on shares of Vor Biopharma in a research note on Thursday, June 26th. Zacks Research lowered Vor Biopharma from a "hold" rating to a "strong sell" rating in a research note on Monday, October 13th. Finally, HC Wainwright restated a "buy" rating and issued a $60.00 target price on shares of Vor Biopharma in a research note on Thursday, August 14th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, three have given a Hold rating and two have given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $77.83.

Hedge Funds Weigh In On Vor Biopharma

Institutional investors have recently modified their holdings of the company. OMERS ADMINISTRATION Corp purchased a new stake in Vor Biopharma during the 1st quarter valued at about $100,000. Goldman Sachs Group Inc. boosted its holdings in Vor Biopharma by 218.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company's stock valued at $61,000 after acquiring an additional 58,247 shares during the period. Money Concepts Capital Corp boosted its holdings in Vor Biopharma by 106.1% during the 1st quarter. Money Concepts Capital Corp now owns 51,535 shares of the company's stock valued at $37,000 after acquiring an additional 26,535 shares during the period. Jane Street Group LLC purchased a new stake in Vor Biopharma during the 1st quarter valued at about $140,000. Finally, XTX Topco Ltd purchased a new stake in Vor Biopharma during the 2nd quarter valued at about $66,000. 97.29% of the stock is currently owned by institutional investors.

Vor Biopharma Company Profile

Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.